Furthermore, it will be interesting to determine whether treatment with the TOP1 poison irinotecan/SN38 instead of the TOP2 poison Etop leads to improved outcomes in AML patients expressing low‐to‐moderate HMGA2 levels in leukemic cells, as implied by the results of our previous work (Ahmed et al., 2019). Here, HMGA2 is linked to acute myeloid leukemia.